Gilead and Novo Nordisk have announced that a study testing various drug combinations for the fatty liver disease known as NASH has checked out in a mid-stage proof-of-concept study.

This project estimates surface-level particulate matter (PM2.5) concentrations using: Satellite-based AOD (Aerosol Optical Depth) Ground-based pollution station data Atmospheric reanalysis ...